drugset / Trial / NCT01411072
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Chemotherapy is given after curative surgery for pancreas cancer to try to improve cure rates. There are two choices of chemotherapy which are currently considered equal treatments: gemcitabine or 5-fluorouracil (5FU). This study is trying to determine if one of two standard chemotherapies is better than the other depending on whether patients have high or low human equilibrative nucleoside transporter 1 (hENT1). hENT1 is a protein that is found in varying amounts on pancreas cancers.
Timeline
- Start
- 2011-09
- Primary completion
- 2015-09
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 425 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 20 mg/m2 | Intravenous |